完成国有控股后 天风证券近三年为鄂企融资近1200亿元

Group 1 - He Yuan Bio, a star enterprise innovating "rice blood-making" technology, recently listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, with its market value increasing from 60 million to over 30 billion, a growth of over 500 times [2] - Tianfeng Securities has been a significant capital force accompanying He Yuan Bio for 15 years, participating in its angel round investment and later in its Pre-IPO round investment [2] - In 2023, Hubei Hongtai Group became the controlling shareholder of Tianfeng Securities, filling the gap of provincial state-owned capital controlling a brokerage and stabilizing local finance [2] Group 2 - In the first nine months of 2025, Tianfeng Securities achieved a total operating income of 2.112 billion, a year-on-year increase of 57.53%, and a net profit attributable to shareholders of 153 million, turning from loss to profit [3] - As of the end of October 2023, Tianfeng Securities' total market value reached 59.23 billion, an increase of 27.57 billion since Hubei Hongtai Group became the controlling shareholder [3] - Tianfeng Securities has facilitated nearly 930 billion in financing for the real economy over the past three years, with around 120 billion for Hubei enterprises [3]